CoChat

Illness Risk Following Rapid Versus Gradual Discontinuation of Antidepressants

Baldessarini, Ross J., Tondo, Leonardo, Ghiani, Carmen, Lepri, Beatrice · 2010 · American Journal of Psychiatry

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Rapid discontinuation of some psychotropic medications is followed by discontinuation symptoms as well as an increased risk of early illness recurrence. Recurrence occurs earlier after rapid than after gradual discontinuation with lithium and antipsychotics. The authors compared illness recurrence after rapid versus gradual discontinuation of antidepressants. METHOD: The authors compared 398 patients with a DSM-IV diagnosis of recurrent major depressive disorder (N=224), panic disorder (N=75), bipolar II disorder (N=62), or bipolar I disorder (N=37). Two-thirds were women, the mean age was 42 years, and patients were treated with antidepressants for a mean of 8.5 months. Antidepressants were discontinued clinically, either rapidly (over 1-7 days; N=188) or gradually (over 14 days or more; N=210), with a mean follow-up duration of 2.8 years; patients who were ill at discontinuation were excluded from the analysis. The authors compared latency to first new illness episodes using survival analysis and Cox multivariate modeling. RESULTS: The latency to first illness with rapid discontinuation was 0.4 times that with gradual discontinuation, and the latency after rapid discontinuation was one-fourth the estimated average previous interepisode interval in the same patients. The effect was similar across antidepressant classes and across years; the pace of discontinuation had less effect with drugs of prolonged half-life. The effect also varied by diagnosis (bipolar I > or = panic > bipolar II > or = major depressive disorder) but not by episodes per year, duration of index illness, use of concomitant treatment, or antidepressant dose or duration. CONCLUSIONS: The recurrence risk for depression or panic was much shorter after rapid than after gradual discontinuation of antidepressants. These findings have implications for both clinical management and the design and interpretation of clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2010.09060880

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Research works printed but not linked: 6

  1. National Center for Health Statistics, 2007, Health United States–2007, 333
  2. Schatzberg AR, 1997, J Clin Psychiatry, 58, 23
  3. Duenwald M, 2004, New York Times, D1
  4. Schatzberg AF, 2006, J Clin Psychiatry, 67, 27
  5. 10.1177/0269881107081550 · doi:10.1177/0269881107081550 · Paper page
  6. Baldessarini RJ : Drug therapy of depression and anxiety disorders, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed . Edited by , Brunton LL , Lazo JS , Parker KL. New York, McGraw-Hill, 2005, pp 429–459

Cited by

Items 101–123 of 123

Metadata

Authors
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B.
Affiliations
Harvard University (US)
Venue
American Journal of Psychiatry
Published
2010-08-01
Volume
167
Issue
8
Pages
934-941
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2170925735
Cited by
123
References
35
Citations by year
2026: 5 · 2025: 9 · 2024: 12 · 2023: 5 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 5 · 2016: 3 · 2015: 6 · 2014: 7 · 2013: 5 · 2012: 16
FWCI
9.62
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r03mh073579-02)
  • National Institute of Mental Health (MH-073579)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
antidepressant discontinuation, major depressive disorder, panic disorder, bipolar disorder, discontinuation symptoms
MeSH terms
Adult, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Risk Factors, Substance Withdrawal Syndrome, Time Factors, Proportional Hazards Models, Survival Analysis, Panic Disorder, Treatment Outcome, Risk Assessment, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.